NCT02857608
Withdrawn
Phase 2
A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus
Overview
- Phase
- Phase 2
- Status
- Withdrawn
- Sponsor
- Cardinal Health 414, LLC
- Primary Endpoint
- Concordance (the proportion of the number of subjects with lymph nodes identified by Lymphoseek and standard of care methods compared to the number of subjects with lymph nodes identified by standard of care methods)
Overview
Brief Summary
Prospective, open-label, within-subject, multi-center pilot study of Lymphoseek in the detection of lymph nodes in subjects with known squamous cell carcinoma of the anus.
Detailed Description
Prospective, open-label, within-subject, multi-center pilot study of Lymphoseek in the detection of lymph nodes in subjects with known squamous cell carcinoma of the anus. All subjects will receive a single dose of 50 µg Lymphoseek radiolabeled with 0.5 millicurie (mCi) (18.5 MBq) 99mTc.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject has provided written informed consent with Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization
- •Has histologically confirmed squamous cell carcinoma of the anus (anal canal or perianus)
- •Has a documented clinical stage using the tumor, lymph node, metastasis staging (TNM) classification system that was established by at least physical exam with manual palpation, digital anorectal examination, high-resolution anoscopy and PET/CT imaging evaluation of the bilateral inguinal area
- •Is at least 18 years of age at the time of consent
- •Has an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 to 3
- •If of childbearing potential, the subject has a negative pregnancy test within 48 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year
Exclusion Criteria
- •The subject has had radiation therapy, chemotherapy or immunotherapy within the 30 days prior to Lymphoseek administration
- •Has had previous surgery or node dissection (exclusive of fine needle aspiration) or radiation to node basins that would be involved in the intraoperative lymphatic mapping procedure
- •Has a known allergy to dextran
- •Is breast-feeding or pregnant
- •Before the administration of Lymphoseek, has received any radiopharmaceutical within 7 radioactive half-lives of that radiopharmaceutical
- •Has received an investigational product within the 30 days prior to Lymphoseek administration
Arms & Interventions
Lymphoseek - 0.5 mCi, 50 ug
Experimental
A single dose of 50 µg Lymphoseek radiolabeled with 0.5 millicurie (mCi) (18.5 MBq) 99m Tc
Intervention: Lymphoseek (Drug)
Outcomes
Primary Outcomes
Concordance (the proportion of the number of subjects with lymph nodes identified by Lymphoseek and standard of care methods compared to the number of subjects with lymph nodes identified by standard of care methods)
Time Frame: 2-5 Days
Secondary Outcomes
- Reverse Concordance (the proportion of the number of subjects with lymph nodes identified by Lymphoseek and standard of care methods compared to the number of subjects with lymph nodes identified by Lymphoseek)(2-5 Days)
- Nodal Concordance (the proportion of the number lymph nodes identified by Lymphoseek and standard of care methods compared to the number of lymph nodes identified by standard of care methods)(2-5 Days)
- Reverse Nodal Concordance (the proportion of the number lymph nodes identified by Lymphoseek and standard of care methods compared to the number of lymph nodes identified by Lymphoseek)(2-5 Days)
- Incidence of Adverse Events(5 Days)
Investigators
Similar Trials
Terminated
Phase 2
A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node DissectionUterine Cervical NeoplasmsNCT02509585Cardinal Health 414, LLC18
Completed
Phase 4
Sentinel Lymph Node Biopsy Findings in Patients With Breast CancerBreast CancerNCT02287675Kettering Health Network40
Terminated
Not Applicable
Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation TherapyBreast NeoplasmsNCT01821768Washington University School of Medicine69
Completed
Phase 1
Pilot Study of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic RhinitisAllergic RhinitisNCT02301884Gachon University Gil Medical Center12
Completed
Not Applicable
A French Observational Study of Indocyanine Green for Patients With Breast Cancer Having a Sentinel Lymph Node Biopsy.Breast CancerNCT06024213BTG International Inc.101